TEMOZOLOMIDE IN PATIENTS WITH GEM OR AA TUMORS AT FIRST RELAPSE

替莫唑胺治疗首次复发的宝石型或AA型肿瘤患者

• 批准号: 6274312
• 负责人: ALEXANDER M SPENCE
• 金额: $ 2.06万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274312
• 关键词: antineoplastics; clinical research; drug administration rate /duration; drug screening /evaluation; glioblastoma multiforme; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; oral administration; procarbazine

To determine the efficacy of Temozolomide defined as progression-free survival at 6 months and safety of Temozolomide when administered orally, once a day for 5 days repeated every 28 days in the treatment of patients with GBM (Glioblas-toma Multiforme) or AA (Anaplastic Astrocytoma) at first relapse. A reference agent procarbazine is included in the study of patients with GBM to verify that objective responses can be obtained using the reference agent.

确定Temozolomide的疗效定义为无进展 6个月的生存以及替莫唑胺的安全性 口服，每天一次每天28天重复一次治疗 患有GBM（胶质布拉斯 - toma多形）或AA（偏长瘤的患者） 星形胶质细胞瘤）在首次复发时。 参考代理人procarbazine是 包括在GBM患者的研究中，以验证该目标 可以使用参考代理获得响应。